Try GOLD - Free
Next-generation surgical robotics stand poised for global revolution
Bio Spectrum
|August 2025
The adoption of robot-assisted surgery has increased significantly in the past decade as opportunities for performing minimally invasive procedures have multiplied.
Robotic-assisted interventions as a proportion of the total number of surgeries have witnessed strong uptake among hospitals, especially in both developed and developing countries such as the United States, Japan, South Korea, China and India. Surgical robotic platforms facilitate more precise surgeries and improve the repeatability of procedural movements. These benefits support faster recovery and better outcomes for patients, which has helped drive their adoption among healthcare providers.
In spite of the many advantages, surgical robotic platforms have drawbacks. Legacy surgical robots involve a large setup that consumes significant space in the operating room. The platforms are not mobile and cannot be transferred from one room to another after installation. Moreover, the instrument setup and positioning of conventional robotic surgical arms before the procedure require considerable effort, which subsequently increases the total operation time frame. The use of rigid instruments in these traditional surgical robotic platforms becomes extremely challenging in nonlinear pathways and makes it difficult to reach anatomical areas such as the brain in a minimally invasive fashion. This has spurred the development of agile and state-of-the-art next-generation surgical robotic technology platforms, which have been built with unique designs, advanced instrumentation, analytics and visualisation technologies that address the limitations of conventional surgical robotic systems.
Small footprint: Next-generation surgical robotic technology platforms have a smaller footprint that makes them easily accommodated in operating rooms without taking up much space. Moreover, these mobile platforms can be rapidly deployed in various operating rooms to facilitate higher utilisation.
This story is from the August 2025 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum
Bio Spectrum
Can India's CDMOS Lead the Next Biopharma Wave?
India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).
8 mins
March 2026
Bio Spectrum
Telangana turns catalyst for innovation
Telangana is at a pivotal moment in its journey as a global life sciences hub.
6 mins
March 2026
Bio Spectrum
Is AI the New Weapon in the Fight to End TB?
A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).
2 mins
March 2026
Bio Spectrum
ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India
US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.
1 min
March 2026
Bio Spectrum
Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy
Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.
5 mins
March 2026
Bio Spectrum
"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"
Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.
5 mins
March 2026
Bio Spectrum
Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer
Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.
1 min
March 2026
Bio Spectrum
Haleon ropes in Kedar Lele as President for India Subcontinent
Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.
1 min
March 2026
Bio Spectrum
Centre revises Startup Recognition Framework to strengthen Startup India Action Plan
The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.
1 min
March 2026
Bio Spectrum
"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"
In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.
5 mins
March 2026
Listen
Translate
Change font size
